本帖最后由 老马 于 2013-3-13 13:43 编辑
2 Z9 \+ e, v/ W& T% i( ?; E
p+ {3 s; a8 W9 K7 h' r健择（吉西他滨）+顺铂+阿瓦斯汀. P# \# Q! _3 A$ f8 d: p
Gemzar +Cisplatin + Avastin
, \# q8 Y% w8 M* Ahttp://annonc.oxfordjournals.org/content/21/9/1804.full1 X0 R0 c: x) @: R8 w4 A& ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 S) w: l9 R4 t, a6 p
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& ?* B' _3 H" r, t! HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: }$ x# V! j' q. E9 n
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 782)
# i& [7 r4 ^$ H+ F. D7 t% y$ u
华为网盘附件：
2 X. H2 f" l# `; k+ e【华为网盘】ava.JPG5 ?( O( x1 w) |# e# o
|
显身卡
